Skip to main content

Advertisement

Table 1 Details of the neoadjuvant chemotherapy (NACT) regimens administered and associated toxicity

From: D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy

Regimen Total number of patients (n = 139) Number of patients who completed the NACT (n = 133)a Toxicity grade
EOX3 87 83 (1 patient received 2 additional cycles) Tolerated toxicities
    Grade I vomiting (5 patients)
    Grade I diarrhea (1 patient)
    Grade I vomiting and diarrhea (2 patients)
    Grade I skin and hair toxicity (1 patient)
    Grade I neutropenia (1 patient)
    Grade II vomiting (3 patients)
    Grade II diarrhea (1 patient)
    Grade II vomiting and diarrhea (1 patient)
    Grade III hand-foot syndrome (1 patient)
    Grade IV diarrhea (1 patient)
    Grade IV thrombocytopenia (2 patients)
    Toxicities resulting in alterations in regimen
    Grade I diarrhea, and on and off febrile illness (1 patient, resulted in reduced cycles)
    Grade III fatigue (1 patient, resulted in reduced cycles)
    Grade III diarrhea (1 patient, resulted in reduced cycles)
    Grade IV vomiting and diarrhea (1 patient, resulted in reduced cycles)
    Grade III vomiting (1 patient, protocol changed to EOF after 1 cycle)
ECF3 24 23 (1 patient received an additional cycle of docetaxel and oxaliplatin) Grade I diarrhea (2 patients)
Grade I vomiting (1 patient)
Grade II vomiting and diarrhea (1 patient)
Grade IV mucositis (2 patients)
Grade IV diarrhea (1 patient)
Grade IV vomiting and diarrhea (1 patient)
Toxicities resulting in alterations in regimen
Grade IV diarrhea (1 patient, resulted in reduced cycles)
EOF3 9 8 Grade I vomiting (1 patient)
Grade I diarrhea (2 patients)
Toxicities resulting in alterations in regimen
Grade IV mucositis (1 patient, resulted in 25% dose reduction and reduced cycles)
Grade III febrile neutropenia (1 patient, resulted in 20% dose reduction)
CAPOX3 7 7 Grade 1 nausea, vomiting (2 patients)
EO3 1 1  
DCF 6 6 (3 patients received 3 cycles each and 1 patient each received 4, 5 and 6 cycles, respectively) Anemia after 1 cycle and grade 1 diarrhea after 2 cycles (1 patient)
Grade II febrile neutropenia (1 patient)
Grade III diarrhea (1 patient)
1 patient developed chicken pox while on chemotherapy
ECX3 5 5 Toxicities resulting in alterations in regimen
Grade 1 nausea and vomiting (1 patient, protocol changed to ECF after 1 cycle)
  1. aSix patients received reduced cycles due to toxicity. E, epirubicin 50 mg/m2 (day 1); C, cisplatin 60 mg/m2 (day 1); F, 5-FU 650 mg/m2 (days 1 to 5); O, oxaliplatin 130 mg/m2 (day 1); X, capecitabine 1000 mg/m2 twice daily (days 1 to 14); D, docetaxel 50 mg/m2 (day 1).